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Abstract: Amyotrophic lateral sclerosis (ALS) is an adult-onset degenerative disease characterized by the loss of upper 
and lower motor neurons, progressive muscle atrophy, paralysis and death, which occurs within 2-5 years of diagnosis. 
Most cases appear sporadically but some are familial, usually inherited in an autosomal dominant pattern. It is postulated 
that the disease results from the combination of multiple pathogenic mechanisms, which affect not only motor neurons but 
also non-neuronal neighboring cells. Together with the understanding of this intriguing cell biology, important challenges 
in the field concern the design of effective curative treatments and the discovery of molecular biomarkers for early 
diagnosis and accurate monitoring of disease progression. During the last decade, transcriptomics has represented a 
promising approach to address these questions. In this review, we revisit the major findings of the numerous studies that 
analyzed global gene expression in tissues and cells from biopsy or post-mortem specimens of ALS patients and related 
animal models. These studies corroborated the implication of previously described disease pathways, and investigated the 
role of new genes in the pathological process. In addition, they also identified gene expression changes that could be used 
as candidate biomarkers for the diagnosis and follow-up of ALS. The limitations of these transcriptomics approaches will 
be also discussed. 
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A BRIEF OVERVIEW ON ALS 
  Amyotrophic lateral sclerosis (ALS), also referred to as 
motor neuron disease or Lou Gehrig’s disease, is a fatal 
condition caused by the selective degeneration of upper 
motor neurons, which originate in the motor cortex and give 
rise to the pyramidal tract, and lower motor neurons, which 
connect the spinal cord and brainstem to skeletal 
musculature. Typical clinical features include progressive 
muscle weakness and atrophy, fasciculations, hyperreflexia, 
dysarthria and dysphagia. ALS most commonly develops 
between 40 and 70 years of age, and affects about two per 
100,000 people. Death often occurs by respiratory 
complications within two to five years of diagnosis [1]. 
About 90% of cases are sporadic, since they are not 
associated with a documented family history. The remainder 
cases are inherited, usually in an autosomal dominant 
pattern. Sporadic and familial forms of the disease are 
clinically and pathologically undistinguishable, suggesting 
common pathogenic mechanisms [2]. Riluzole, which is 
postulated to fight against motor neuron death by preventing 
glutamate-induced excitotoxicity, is the only approved 
medication for the treatment of ALS but merely prolongs 
patient’s survival for several months [3]. 
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  Numerous genetic factors have been shown to predispose 
to ALS or to be associated with (mostly atypical) forms of 
the disease [http://alsod.iop.kcl.ac.uk/]. In addition, specific 
mutations have been found in a small group of genes that 
cause directly ALS. These genes encode a variety of 
proteins, such as the antioxidant enzyme Cu/Zn superoxide 
dismutase (SOD1) [4], and the RNA processing regulatory 
factors TAR DNA binding protein 43 (TDP-43) [5] and 
fused in sarcoma/translocated in liposarcoma (FUS/TLS) [6]. 
The etiology of the selective degeneration of motor neurons 
in ALS, whatever familial or sporadic, still remains elusive. 
Many pathogenic mechanisms have been shown to be 
involved, including protein misfolding [7], mitochondrial 
dysfunction [8], oxidative damage [9], altered DNA/RNA 
processing [10], energy imbalance [11], defective axonal 
transport [12], excitotoxicity [13], insufficient growth factor 
signaling [14] and inflammation [15]. During the last years, 
the situation has become more complex than imagined, 
because it is postulated that the pathogenic process 
implicates not only motor neurons but also non-neuronal 
neighboring cells, such as astrocytes [16] and microglial 
cells [17] and, beyond the central nervous system, skeletal 
myocytes [18] and, likely, other cells in the body. 
  The diagnosis of ALS is exclusively based on clinical 
examination, supportive electrophysiological findings, 
medical history, and exclusion of confounding disorders that 
mimic the disease [19]. During the early stages of ALS, not 
all patients present with the same symptoms, which usually 
start at one point and then spread to other parts in the body in 
a quite variable manner from one person to another. Only the Transcriptomics in ALS  Current Genomics, 2011, Vol. 12, No. 7    507 
worsening of the symptoms and signs indicating both upper 
and lower motor neuron pathology can assess the presence of 
ALS. In average, the confirmation of diagnosis from the 
onset of symptoms takes 13–18 months [20]. There is 
therefore an unmet need for finding specific and sensitive 
molecular markers (or biomarkers), which could help with 
earlier diagnosis and more precise monitoring of disease 
progression. 
  During the last few years, numerous “omics” approaches 
have attempted to identify from a global perspective changes 
in the expression of genes, or in the amount of proteins and 
metabolites that could shed light into the pathogenesis of 
ALS or be used as biomarkers of disease [21-23]. 
Particularly, studying the transcriptome allows to determine 
the combined expression of thousands of genes in organs, 
tissues or cells at different stages of a given pathology. At 
the time of first transcriptomics studies on ALS, the 
technology was at its beginning and only capable of 
screening between hundreds and several thousands of 
transcripts. The sophistication of the microarrays rapidly 
enhanced their ability to measure at once more than 30,000 
transcripts. Nowadays, one can obtain a complete overview 
of the expression of the entire genome, by analysing not only 
whole genes but also their related splice variants. These 
technological improvements have resulted in detecting more 
and more significant expression changes, affecting less than 
a hundred of genes in pioneering studies [23-25] and more 
than 2,000 in the latest ones [26, 27]. The exponential 
increase in the number of genes that appear differentially 
expressed in ALS points out the complexity of the disease 
and the diversity of the pathways involved in promoting or 
preventing neurodegeneration. These findings have been 
accompanied by a shift in the conceptual understanding of 
ALS. While initial studies were restricted to the analysis of 
gene expression changes in whole tissue samples from the 
central nervous system (CNS) [28, 29], follow-up studies 
refined their experimental designs to better decipher the 
nature of the puzzling non-cell autonomous paradigm of 
ALS [30, 31]. The objective of this review is to revisit the 
numerous studies that analysed the gene expression profiles 
of tissues and cells from biopsy or post-mortem specimens 
of ALS patients and related animal models. Such studies 
provided insight into previously described disease 
mechanisms, and investigated the role of new genes involved 
in the pathological process. In addition, promising results 
were obtained for several potential biomarkers, which could 
be used in clinics. The limitations of these transcriptomics 
approaches will be also discussed. 
TRANSCRIPTOMICS FOR THE ANALYSIS OF ALS 
PATHOGENESIS 
Gene Profiling in Post-Mortem Human ALS Tissue 
  The first ALS transcriptomics study was released in 2001 
and concerned patients presenting with the sporadic form of 
the disease [23]. This study, as well as others undertaken 
since then, focused on the understanding of the process of 
motor neuron death as such, using autopsy specimens of 
mainly spinal cord [23, 24, 28, 29, 32] but also motor cortex 
[33, 34]. The generated gene expression profiles showed the 
activation of several mechanisms classically associated with 
ALS at disease endpoint [2], including activation of cell 
death and survival pathways [23, 28, 29, 33-35], response to 
oxidative stress [23, 24, 28, 33, 34] and inflammation [23, 
24, 33, 34], and protease activity [23, 24, 28, 33, 34] (Fig. 1). 
  In addition, these studies also showed the implication of 
new pathways relevant to ALS and, in some cases, predicted 
later observations obtained by other means. For instance, 
expression changes were found in the CNS for genes 
involved in lipid metabolism [23, 34-36], including 25-
cholesterol hydroxylase [23], apolipoprotein E [36] and 
oxysterol binding protein-like 11 [34] genes, which suggests 
that cholesterol metabolism is altered in ALS. Interestingly, 
strong evidence now supports the role of a defective energy 
metabolism at the whole body level in the onset and 
progression of ALS [18] and, in particular, it has been shown 
that hyperlipidemia is a significant prognostic factor for 
patient’s survival [37]. Transcriptomics studies on human 
CNS also highlighted changes in the expression of genes 
related to axonal transport and the cytoskeleton [28, 29, 33-
35]. Among these, the expression of dynactin and dynein, 
which play a key role in intracellular trafficking, was found 
to be down-regulated [29, 35]. Dynactin dysfunction might 
be detrimental to motor neurons as it would block axonal 
transport [38]. Curiously, a mutant dynactin gene variant has 
been found to occur in familial cases of ALS [39]. Another 
important conclusion of the CNS gene expression profiles 
was the alteration of the processing of RNA [23, 24, 28, 29, 
35], which is in agreement with recent discoveries reporting 
the identification of mutant forms of TDP-43 and FUS/TLS, 
both being involved in RNA processing, in several pedigrees 
of ALS patients [40].  
Gene Profiling in SOD1(G93A) Transgenic Rodent 
Models of ALS 
  The findings based on post-mortem human ALS tissues 
cannot ascertain whether altered gene expression is a 
secondary marker of neurodegeneration or the cause of it. In 
contrast, animal models of disease allow to collect samples 
not only at every step of the pathological process but also 
during the pre-symptomatic phase, when initiatory 
pathogenic events can arise at the molecular level. Moreover, 
the quality of RNAs extracted from animal samples is 
generally higher as delay between sacrifice and collection is 
normally short and can be easily controlled. A subset of 
patients with autosomal dominantly inherited ALS harbor 
point mutations in the gene encoding SOD1, which is a free 
radical scavenging enzyme that protects cells against 
oxidative stress [4]. The identification of these mutations 
allowed the production of transgenic mice overexpressing 
different mutated SOD1 genes. Nowadays, the SOD1(G93A) 
strain is the most commonly used model of ALS. These mice 
develop a precipitous, age-related loss of motor neurons, 
together with related clinical symptoms (i.e. altered hind 
limb extension reflexes, muscle weakness and paralysis), 
that strongly resembles human ALS, and represent a 
valuable model to investigate the molecular mechanisms 
underlying the disease [41]. 
  In the spinal cord of pre-symptomatic SOD1(G93A) 
mice, gene expression changes appeared modest [25, 42, 43], 
and were mostly concerned with metabolic alterations [44], 
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disturbances [42]. Of note, the expression of the intermediate 
filament vimentin was consistently found to be up-regulated 
in several studies [25, 42, 45]. Vimentin plays an important 
role in the organization of the cytoskeleton and interacts with 
dynein to mediate neurite outgrowth [46]. Using laser-
captured microdissected spinal motor neurons, Perrin et al. 
[45] showed that the up-regulation of vimentin mostly 
occurred within these cells, and postulated that its 
aggregation might lead to neurodegeneration. In the spinal 
cord of SOD1(G93A) mice at an early stage of disease, when 
first symptoms arrive, the gene profiles revealed that the 
changes already detected during the pre-symptomatic phase 
gained in intensity [25, 42-44]. In addition, other cellular 
processes appeared affected at the transcriptional level, 
including mainly the response to oxidative stress and 
inflammation and, to a lesser extent, pro-survival 
mechanisms, proteasome activity, and RNA processing. 
Curiously, the expression of genes involved in cell death 
pathways was not significantly up-regulated specifically 
within motor neurons, indicating that the loss of these cells is 
a late event in the disease [44, 45]. Finally, the pattern of 
gene expression in the spinal cord of SOD1(G93A) mice at 
end stage was very similar to that found in post-mortem 
specimens of human ALS, and affected genes involved in 
cell death [25, 43, 47] and neuroprotection [43, 44], 
inflammation [25, 43, 47], proteasome function [25, 42, 43], 
metabolism [25, 42, 47], cytoskeleton and axonal guidance 
[25, 42-44, 47] (Fig. 1). 
  It is now commonly accepted that motor neuron 
degeneration in ALS is the result of the combined 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). Major gene expression changes in ALS. 
Schematic representation of the most important findings from studies performed on human ALS and their related mutant SOD1 transgenic 
models. Upper lines represent disease progression in patients, and lower lines represent disease progression in animals. Gene functional 
categories are indicated for different tissues or cells. The inset shows the progression of the cellular events and clinical symptoms 
corresponding to each pathological stage in the mouse (pre-symptomatic, early symptomatic and late symptomatic). N/A, not available; 
surv., survival; comm., communication. 
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participation of several cell types, including the motor 
neurons themselves and other non-neuronal neighboring 
cells [2]. Thus, it can be envisaged that the transcriptional 
profile of motor neurons, whatever embedded into the spinal 
cord or isolated by microdissection, is imprinted by their 
cellular environment. Consequently, it cannot be clearly 
established whether particular gene expression changes are 
intrinsically motor neuron-specific or the consequence of 
cell-to-cell interactions. Several studies prompted to bypass 
this difficulty by analysing the transcriptome of cells, 
including cortical neurons [48] and spinal cord astrocytes 
[49], which were isolated from SOD1(G93A) mouse and rat 
embryos, respectively, and then kept in culture. Other studies 
preferred to use NSC34 [50] or SH-SY5Y [51] neuronal cell 
lines transfected with mutant SOD1(G93A). In general, 
many of the expression changes detected by these 
approaches were similar to those found in the human and 
animal studies. 
  Together with the studies that focused on the progression 
of disease in SOD1(G93A) mice, it is noteworthy that the 
use of this animal model also allowed to analyze the 
transcriptome in response to induced stress, which can give 
access to potential intrinsic deficiencies owing to mutant 
SOD1 toxicity. Recently, Jokic et al. [52] investigated the 
gene expression profile of the spinal cord in SOD1(G93A) 
rats in response to mild compression. Shortly after injury, the 
expression of genes involved in inflammation and apoptosis 
was significantly increased while that of genes related to 
angiogenesis appeared reduced. Later on 7 days post-injury, 
the expression pattern was characterized by down-regulation 
of pro-survival genes and up-regulation of genes implicated 
in axonal transport and metabolic pathways. It was proposed 
that mutant SOD1 predisposes to functional impairment that 
becomes visible, already at a pre-symptomatic age, under 
particular stress conditions. 
Gene Profiling in other Mutant SOD1 Transgenic Models 
of ALS 
  A new transgenic line, the SOD1 L126 delTT mouse, 
was generated by expressing a truncated form of SOD1 that 
leads to pathological features and motor neuron degeneration 
similar to that observed in ALS [53]. Recently, Fukada et al. 
[54] analyzed the transcriptome in whole spinal cord extracts 
from pre-symptomatic and diseased animals, and found that 
the most important changes in gene expression were related 
to inflammation. Moreover, changes were modest in pre-
symptomatic mice, and concerned genes involved in RNA 
processing and protein synthesis. At disease stage, an 
increased number of expression changes affected genes 
implicated in inflammation and neuroprotection but also 
protein degradation and cell death. Interestingly, 
immunohistochemistry validation of several of these gene 
expression changes revealed that such transcriptional 
regulations came from glial cells and not motor neurons, 
which is consistent with the marked inflammatory trait 
observed in this mouse line. 
  Although still debated, growing evidence suggests that 
primary muscle abnormalities may occur in ALS. Muscle 
restricted expression of mutant SOD1 was sufficient to 
trigger muscle atrophy and mitochondrial dysfunction [55]. 
In addition, mild uncoupling of mitochondrial respiration in 
skeletal muscle was sufficient to affect neuromuscular 
junction stability and function, and induce distal 
degeneration of motor neurons [56]. A recent study used 
SOD1(G86R) mice, which harbour another point mutation in 
the SOD1 gene different from that of the G93A line [57], 
and characterised the gene profile in skeletal muscle during 
the course of ALS [30]. As previously exposed in the case of 
the spinal cord, only modest gene expression changes were 
found in the muscle of pre-symptomatic SOD1(G86R) mice. 
In contrast, significant transcriptional changes appeared at 
the moment of first clinical symptoms (i.e. altered hind limb 
extension reflexes), affecting genes mostly involved in cell 
cycle, growth and differentiation, cytoskeleton, and the 
response to stress and inflammation. At the onset of hind 
limb paralysis, the whole transcriptome changes gained in 
intensity, indicating advanced atrophy. Because motor 
neuron loss is a late event in SOD1(G86R) mice, the 
progression of the gene expression changes detected in 
muscle was consistent with the notion that the degeneration 
of lower motor neurons proceeds in a distal to proximal 
dying-back pattern. 
Gene Profiling in Transgenic Mouse Models of ALS 
Unrelated to Mutant SOD1 
  Initially generated to investigate the effects of hypoxia on 
the biological functions of vascular endothelial growth factor 
(VEGF), VEGF-delta/delta mice harbor a deletion of the 
hypoxia-responsive element in the promoter sequence of the 
VEGF gene. Surprisingly, the phenotype of these mice 
closely resembles that of ALS, including the presence of 
muscle weakness, axonal degeneration and spinal motor 
neuron loss. However, such an ALS-like syndrome is not 
progressive, and the lifespan of VEGF-delta/delta mice is not 
compromised. Using laser-captured microdissected spinal 
motor neurons from this animal model, Brockington et al. 
[58] showed that the gene profile in VEGF-delta/delta mice 
at the symptomatic stage was quite similar to that observed 
in diseased SOD1(G93A) mice. In contrast, important 
expression changes concerning genes involved in oxidative 
metabolism were already detected before disease. It was 
proposed that some kind of metabolic dysfunction is an early 
event in this model, which may predispose to perturbed 
axonal maintenance and subsequent dying-back of motor 
neurons. 
  Very recently, two mouse lines overexpressing mutant 
ALS-linked and wild-type TDP-43 were generated, and the 
transcriptome in the cortex of these mice was analyzed [26]. 
The observed expression changes mainly concerned genes 
involved in response to stimulus and chromatin assembly, 
which is consistent with the role of TDP-43 in regulating 
gene expression and splicing events. Interestingly, these 
transcriptional changes occurred in both mutant and wild-
type mice, suggesting that the toxicity of TDP-43 might be 
due to its accumulation rather than to the fact that the protein 
was mutated. 
Gene Profiling in Healthy Wild-Type Mice 
 To better understand the complex pathogenic 
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studies preferred to investigate the transcriptome of healthy 
motor neurons in response to induced stress, or the intrinsic 
characteristics of different populations of motor neurons as a 
means to elucidate vulnerability factors. Then, the findings 
could be extrapolated to the disease condition. The cause-
and-effect relationship between physical activity and the 
development of ALS is a matter of controversy, since it is 
not well established yet whether some kind of exercise could 
be considered either as a risk factor for the disease [59] or 
beneficial, at least in the animal [60]. Ferraiuolo et al. [61] 
studied the gene profiles of isolated spinal motor neurons 
and skeletal muscle after submitting the mice to physical 
activity in the form of running-like exercise. Major 
expression changes in motor neurons concerned genes 
implicated in growth factor pathways and axonal transport. 
Genes involved in neovascularization and myogenesis 
appeared regulated in the gastrocnemius muscle. It was 
suggested that deficiencies in these cellular processes in one 
or both compartments of the motor unit might lead to a 
perturbed response to mechanical stress and subsequent 
neuromuscular pathology. Another study also addressed this 
question by analyzing the transcriptome of the whole spinal 
cord of mice subjected to physical activity [62]. In this case, 
genes involved in metabolism, and transcription regulation 
were up-regulated while genes involved in glutamate 
signaling were down-regulated. Statistical testing was 
however not performed, so that proper conclusions could not 
be obtained. 
  In ALS, motor neurons in the spinal cord and motor 
cortex are more prone to degeneration than motor neurons in 
the oculomotor nucleus, the function of which remains quite 
preserved during the whole disease process [63]. To better 
understand the reasons of such a discrepancy, Hedlund et al. 
[64] undertook the characterization of the transcriptome of 
these two subtypes of motor neurons in healthy animals. 
Major differences in gene expression between spinal and 
oculomotor motor neurons concerned pathways known to be 
involved in the physiopathology of ALS, such as 
mitochondrial dysfunction, altered RNA processing and 
perturbed axonal transport. Of note, it was found that the 
expression of peripherin, the aggregation of which has been 
related to axonal dysfunction in ALS [65], was higher in 
spinal motor neurons than oculomotor motor neurons. The 
latter, in contrast, showed an enhanced expression of genes 
with protective functions, such as growth factors, suggesting 
a higher stimulation of autocrine neuroprotective pathways. 
These findings indicated that spinal motor neurons might be 
intrinsically more sensitive to stress and subsequent disease. 
SEARCHING FOR BIOMARKERS OF ALS BY 
TRANSCRIPTOMICS 
  The use of transcriptomics as a means to determine gene 
expression changes of diagnostic or prognostic value 
represents a promising approach for the management of ALS 
patients, since the identification of such a kind of biomarkers 
would greatly help to get earlier diagnosis and to monitor 
more precisely disease progression, not only in clinical 
practice but also in the context of therapeutic trials. Several 
studies have addressed these questions by analyzing the 
transcriptome of peripheral blood cells and skeletal muscles 
(Table  1), which allow easy or relatively mild invasive 
access for sampling. 
  Using peripheral blood cells from patients with sporadic 
ALS, Saris et al. [66] found important changes in the 
expression of genes mainly involved in RNA processing and 
mitochondrial function. They generated two subsets of 
candidate biomarkers, each containing several hundreds of 
genes, that showed up- or down-regulated expression, 
respectively, as compared to that observed in a group of 
healthy subjects. Interestingly, no significant relationship 
was found between the detected gene expression changes 
and several clinical variables, including age, gender and site 
of onset of disease (that is, bulbar versus spinal). These 
findings prompted the authors to propose that such a 
persistent differential gene expression could be specific to 
ALS. Another study that focused on the activation of 
peripheral monocytes/macrophages in ALS [67] revealed the 
increased expression of a series of genes implicated in the 
pro-inflammatory LPS/TLR4 signaling pathway. These gene 
expression changes occurred independently of disease 
duration and clinical status, except for the expression of 
alpha-1-acid glycoprotein, the increase of which correlated 
with the ALSFRS-R score, a functional rating scale that 
assesses the activities of daily living in patients with ALS.  
  An original approach was presented by Kudo et al. [31], 
who compared the pre-symptomatic transcriptomes of motor 
neurons and glial cells between SOD1(G93A) mice and Tau 
P301L mice, which is a model of neurodegeneration 
showing typical ALS-like features (including loss of motor 
neurons, reactive gliosis, and muscle weakness and atrophy), 
as well as other degenerative signs in the cerebellum, 
hypothalamus and hippocampus [68]. It was assumed that 
the genes with common differential expression in the two 
models could be considered as candidate biomarkers of ALS. 
By this approach, the authors identified three genes, 
encoding neurofilament heavy chain, peripherin and 
monoglyceride lipase, as being dysregulated in both CNS 
and peripheral blood cells of pre-symptomatic animals. 
  Using muscle biopsies, a recent study attempted to 
identify disease biomarkers in patients with ALS and 
multifocal motor neuropathy (MMN), which is a treatable 
condition that can be mistaken for ALS [27]. The expression 
of several genes, involved in cell cycle, differentiation, 
survival and growth, was shown to be up-regulated only in 
the ALS condition, as compared to a group of healthy 
subjects. These changes were proposed as candidate 
biomarkers for diagnosis, but the findings could not be 
conveniently validated. Another study focused on the 
identification of gene expression changes that could be 
markers of disease progression in muscle biopsies from 
patients with sporadic ALS at different pathological stages 
[69]. Major changes in differentially expressed genes, as 
compared to that observed in healthy subjects, concerned 
neuromuscular transmission and the contractile machinery, 
as well as muscle development and growth. A set of one 
hundred and a half genes distinguished patients at an 
advanced stage from patients with no clinical or 
electrophysiological signs in the biopsied muscle. Among 
these, the expression of a reduced subset of nine genes, 
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Table 1.  Potential Candidates for Specific Biomarkers for ALS 
Study Tissues  Purpose  Patients  Biomarkers 
Module 1 : 500 upregulated genes 
Saris et al. [66]  Blood cells  Diagnostic 
123 ALS 
123 controls 
Module 2: 500 downregulated genes 
Interferon alpha-inducible protein 6 
G protein-coupled receptor 43 
Interferon-induced protein with tetratricopeptide repeats 2 
Alpha-1-acid glycoprotein 
Peptidase inhibitor 3 
Chitinase 3-like 1 
Interleukin 1 receptor antagonist 
Zhang et al. [67]  Blood cells  Diagnostic 
20 ALS 
22 controls 
TNF-related apoptosis inducing ligand 
Sestrin 3 
Collagen, type XIX, alpha-1 
CXorf64 
Leucine-rich repeat kinase 2 
Ceramide kinase-like 
Shtilbans et al. [27] 
Prognator, gracilis, 
and gastrocnemius 
muscles 
Diagnostic 
3 ALS 
3 MMN 
3 controls 
Follistatin 
Cholinergic receptor, nicotinic, alpha 1 
Myosin binding protein H 
Myogenin 
Ras-related associated with diabetes 
Cholinergic receptor, nicotinic, gamma 
Growth arrest and DNA-damage-inducible protein GADD45 
alpha 
Ankyrin repeat domain 1 
Zinc finger protein 36, C3H type-like 2 
Pradat et al. [69]  Deltoid muscle  Prognostic 
9 ALS 
10 controls 
Ankyrin repeat domain 10 
 
discriminated between early and advanced stages of the 
muscle pathology, as determined by the manual muscle 
testing, electromyography and histological examination of 
the degree of muscle atrophy. 
TRANSCRIPTOMICS FOR ALS, RIGHT OR WRONG? 
  Most of the studies we presented herein placed the 
microarrays at the center of the work. This approach is 
evolving, since current studies rather use the transcriptomics 
technology as part of complex analyses of the pathogenic 
role of a particular gene, by applying many other 
experimental means. For example, Cox et al. [70] 
investigated the implication of frontotemporal lobar 
dementia-linked CHMP2B mutations in lower motor neuron 
predominant ALS, by combining genetic sequencing, gene 
profiling and subsequent characterization of the cellular 
pathways involved. In another example, Fiala et al. [71] used 
the microarrays to confirm the role of previously identified 
inflammatory factors in ALS induced by mutant SOD1. 
  Regardless of its relative importance in a given study, 
transcriptomics still faces a number of problems, which can 
be summarized as follows: 
  (1)  Thresholds. Due to the use of necessary but 
arbitrary thresholds for filtering purposes, many gene 
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systematically neglected. In addition, many of these 
small changes in gene expression will appear as false 
negative results when the number of samples is too 
small to allow robust statistical testing. These 
handicaps can account for the small number of gene 
expression changes occurring during the pre-
symptomatic stages of ALS [42, 43]. Increasing the 
number of samples might bypass this difficulty. 
  (2) Translation. The changes in mRNA levels do not 
necessarily translate into modifications in protein 
amounts. Classically, findings from gene profiling 
studies have been validated by additional sets of 
experimental approaches, including immunohisto-
chemistry [29, 31-33, 35, 45, 52, 54, 71] and Western 
blot [25, 27, 31, 33, 52]. However, combining 
transcriptomics with proteomics and/or metabolomics 
should enrich the interpretation of the results. 
  (3)  Animal models. Most of transcriptomics data 
come from the mutant SOD1 mouse model of ALS. 
Other new models of ALS-like motor neuron 
degeneration are now available to the scientific 
community, such as mutant FUS overexpressing rats 
[72] or p150Glued G59S dynactin mice [73]. Studies 
on the transcriptome in these animals and comparison 
with previous data would allow identification of 
common gene expression changes in a disease-
specific manner. 
  (4)  Study design. Studies that focused on the 
discovery of biomarkers specific to ALS typically 
used healthy subjects as controls. From a clinical 
point of view, however, comparing patients with ALS 
to patients presenting with confounding disorders 
should provide more appropriate biomarkers of 
specificity. In addition, the analysis of the 
transcriptome in asymptomatic individuals from an 
ALS pedigree harboring a known causative mutated 
gene, although ethically challenging, would enable 
the detection of very early gene expression changes 
directly linked to the pathogenic mechanism(s) of the 
disease rather than being the consequence of the 
pathological process. 
  (5) Use of blood cells. One could ask whether blood 
cells are a valuable source of biomarkers, when 
considering the neuromuscular nature of ALS. It 
seems, however, that these peripheral cells take 
advantage of the expression of essential genes that 
could be generally affected during disease [66]. Of 
note, changes in the expression of specific genes have 
been shown to occur at the peripheral level in the 
context of other neurodegenerative diseases [66]. In 
addition, inflammatory events have been reported to 
take place in ALS [74], a part of which can be found 
at the periphery [67, 71]. 
  (6)  Use of muscles. Major advantages of using 
skeletal muscle tissue to search for ALS biomarkers 
are that this tissue is easily accessible, and is directly 
affected by the disease, at an early stage that precedes 
motor neuron death [75]. However, collecting muscle 
biopsies remains relatively invasive, and is not part of 
the work-up for the diagnosis of ALS. Moreover, 
multiple testing on the same patient is often not 
ethically feasible. In contrast, a needle biopsy 
technique would offer the opportunity to obtain 
muscle specimens by a less invasive procedure. 
  Despite a certain number of limitations, it is concluded 
that transcriptomics remains a powerful tool to investigate 
whole gene expression in ALS. Interestingly, the generated 
databases, even if a priori misunderstood, can provide very 
valuable information many years later. A good example 
comes from the first ever transcriptomic microarray in the 
field. In 2001, the expression of granulin [23] was found to 
be altered in ALS. Later, it was observed that the granulin 
gene was linked to frontotemporal lobar dementia [76], 
which has been shown to share intriguing physiopathological 
relationships with ALS [40]. 
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